Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2026 16:02 ET | Source: Anteris Technologies Global Corp.

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
January 22, 2026 16:01 ET | Source: Anteris Technologies Global Corp.

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
January 20, 2026 22:53 ET | Source: Anteris Technologies Global Corp.

Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company...
January 20, 2026 16:01 ET | Source: Anteris Technologies Global Corp.

Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic

MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company...
November 17, 2025 06:00 ET | Source: Anteris Technologies Global Corp.

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves
November 12, 2025 17:52 ET | Source: Anteris Technologies Global Corp.

Anteris Announces Results for the Third Quarter of 2025

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reports financial results for the quarter ended September 30, 2025, and provides a corporate update.
November 03, 2025 07:00 ET | Source: Anteris Technologies Global Corp.

FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and...
October 28, 2025 18:08 ET | Source: Anteris Technologies Global Corp.

Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year

Anteris DurAVR THV demonstrates favorable hemodynamics in small annuli patients with no valve related mortality at one year - TCT oral presentation
October 27, 2025 17:43 ET | Source: Anteris Technologies Global Corp.

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Anteris Technologies Announces First Patients Treated in the DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
October 27, 2025 08:43 ET | Source: Anteris Technologies Global Corp.

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed...